ViroChannel brings together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
Recent Updates in Treating Special Populations Living With HIV
with Prof. Christine Katlama, Dr. Gilles Pialoux, Dr. Réjean Thomas and Dr. Mark Wainberg
In this panel discussion, moderated by Prof. Christine Katlama, Prof. Gilles Pialoux, Dr. Mark Wainberg and Dr. Réjean Thomas discuss the different aspects and challenges in managing vulnerable populations, either in terms of viral resistance, treatment choices, and co-infection, such as Hepatitis.
In addition, these experts further discuss Late Presenters and intravenous drug users; who find themselves being taken care of too late in their illness. The experts also explore the importance of accessible services for these vulnerable populations, including street presence, thereby increasing contact with these populations, whom at times escape the usual avenues to our medical system.
This activity is supported
by an educational grant from:
KEY LEARNING POINTS
- New advances in treatment and their impact in terms of viral resistance
- Understand and define the Late Presenters as well as the challenges these patients face in their treatment
- Learn how to better manage intravenous drug users
- Managing hepatitis in patients who are intravenous drug users
- The need for a potentially new treatment management model to reach these vulnerable populations
- Better ways to educate in terms of new treatments in hopes of early testing and early treatment management
Christine Katlama, MD
Department of Infectious and Tropical Diseases
Gilles Pialoux, MD
Infectious Disease Services
Réjean Thomas, MD
CEO | Founder
Clinique médicale l’Actuel:
Centre of Excellence HIV–STI–Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
Mark Wainberg, PhD
McGill AIDS Centre
Medicine, Microbiology and Immunology
Montréal, Québec, Canada
Christine Katlama, MD has a financial interest/relationship or affiliation: MSD, BMS, ViiV, Janssen, Gilead.
Gilles Pialoux, MD has a financial interest/relationship or affiliation: MSD, Gilead, BMS, Abbott, ViiV Healthcare, Janssen, Nephrotek.
Réjean Thomas, MD has a financial interest/relationship or affiliation: Janssen, Abbott, Merck, BMS, Gilead Sciences, ViiV Healthcare.
Mark A. Wainberg, PhD currently has no financial interests/relationships or affiliations in relation to this activity.
Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.